Immunotherapy for hepatocellular carcinoma: current status and future prospects
Z Liu, X Liu, J Liang, Y Liu, X Hou, M Zhang… - Frontiers in …, 2021 - frontiersin.org
Hepatocellular carcinoma (HCC) is the most prevalent primary liver cancer with poor
prognosis. Surgery, chemotherapy, and radiofrequency ablation are three conventional …
prognosis. Surgery, chemotherapy, and radiofrequency ablation are three conventional …
[HTML][HTML] Immunotherapy for hepatocellular carcinoma: Current status and future perspectives
DS Mandlik, SK Mandlik… - World Journal of …, 2023 - ncbi.nlm.nih.gov
Hepatocellular carcinoma (HCC) is one of the world's deadliest and fastest-growing tumors,
with a poor prognosis. HCC develops in the context of chronic liver disease. Curative …
with a poor prognosis. HCC develops in the context of chronic liver disease. Curative …
Tislelizumab vs sorafenib as first-line treatment for unresectable hepatocellular carcinoma: a phase 3 randomized clinical trial
S Qin, M Kudo, T Meyer, Y Bai, Y Guo, Z Meng… - JAMA …, 2023 - jamanetwork.com
Importance Hepatocellular carcinoma (HCC) is a leading cause of cancer-related mortality,
and additional first-line treatments are needed. The programmed cell death protein 1 …
and additional first-line treatments are needed. The programmed cell death protein 1 …
First-line immune checkpoint inhibitor-based combinations in unresectable hepatocellular carcinoma: current management and future challenges
A Rizzo, AD Ricci, G Gadaleta-Caldarola… - Expert Review of …, 2021 - Taylor & Francis
Introduction Immunotherapy has recently taken on an extremely important role in medical
oncology, as first-or later-line treatment in several tumor types, and recent years have seen …
oncology, as first-or later-line treatment in several tumor types, and recent years have seen …
[HTML][HTML] Biochemical predictors of response to immune checkpoint inhibitors in unresectable hepatocellular carcinoma
A Rizzo, G Brandi - Cancer treatment and research communications, 2021 - Elsevier
Hepatocellular carcinoma (HCC) represents the most commonly diagnosed liver cancer
worldwide, and the overall survival of patients with unresectable disease is poor. In the last …
worldwide, and the overall survival of patients with unresectable disease is poor. In the last …
Efficacy and biomarker analysis of CD133-directed CAR T cells in advanced hepatocellular carcinoma: a single-arm, open-label, phase II trial
H Dai, C Tong, D Shi, M Chen, Y Guo, D Chen… - …, 2020 - Taylor & Francis
Expressed by cancer stem cells of various epithelial cell origins and hepatocellular
carcinoma (HCC), CD133 is an attractive therapeutic target for HCC. The marker CD133 is …
carcinoma (HCC), CD133 is an attractive therapeutic target for HCC. The marker CD133 is …
Atezolizumab in advanced hepatocellular carcinoma: good things come to those who wait
A Rizzo, AD Ricci, G Brandi - Immunotherapy, 2021 - Taylor & Francis
Advanced hepatocellular carcinoma (HCC) patients present poor prognosis. However,
recent years have seen the advent of several novel treatments in this setting, where the role …
recent years have seen the advent of several novel treatments in this setting, where the role …
Tislelizumab in patients with previously treated advanced hepatocellular carcinoma (RATIONALE-208): a multicenter, non-randomized, open-label, phase 2 trial
Introduction: Tislelizumab (anti-programmed cell death protein 1 antibody) showed
preliminary antitumor activity and tolerability in patients with advanced solid tumors …
preliminary antitumor activity and tolerability in patients with advanced solid tumors …
Phase 1 randomized trial of stereotactic body radiation therapy followed by nivolumab plus ipilimumab or nivolumab alone in advanced/unresectable hepatocellular …
Purpose Immunotherapy has emerged as a promising therapeutic option for advanced or
unresectable hepatocellular carcinoma (HCC). However, survival remains poor with only a …
unresectable hepatocellular carcinoma (HCC). However, survival remains poor with only a …
[HTML][HTML] Oncolytic virus-based hepatocellular carcinoma treatment: Current status, intravenous delivery strategies, and emerging combination therapeutic solutions
X Li, X Sun, B Wang, Y Li, J Tong - Asian journal of pharmaceutical …, 2023 - Elsevier
Current treatments for advanced hepatocellular carcinoma (HCC) have limited success in
improving patients' quality of life and prolonging life expectancy. The clinical need for more …
improving patients' quality of life and prolonging life expectancy. The clinical need for more …